Stockscreener 앱 받기
0.013
38.10%
-0.008
Telesis Bio Inc 주식(TBIO)의 최신 뉴스
Statement of Changes in Beneficial Ownership (4) - ADVFN
Current Report Filing (8-k) - ADVFN
Small Company Offering and Sale of Securities Without Registration (d) - ADVFN
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Global mRNA Synthesis and Manufacturing Market to Increase at a Steady Growth Rate of ~4% by 2032 | DelveInsight - GlobeNewswire
Telesis Bio Inks Regeneron Deal - San Diego Business Journal
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - Insider Monkey
Telesis Bio and Regeneron Partner on Gene Synthesis - Technology Networks
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis - Yahoo Finance
Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis - MedCity News
What is going on with the stock tbio - AInvest
Telesis Bio Bullish on Future After Whirlwind Year - San Diego Business Journal
FT ranking: The Americas’ Fastest-Growing Companies 2025 - Financial Times
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis - Yahoo Finance
Nuclera appoints William J. Kullback as Non-Executive Director - Cambridge Network
From California to Cambridge: finance ace strengthens Nuclera board - Business Weekly
Carver Bancorp Leads 3 Noteworthy US Penny Stocks - simplywall.st
Telesis Bio secures $3 million in promissory notes By Investing.com - Investing.com Nigeria
Telesis Bio Inc. Faces Financial Challenges Amidst Revenue Decline - TipRanks
Telesis Bio Inc. (TBIO) Quarterly 10-Q Report - qz.com
Telesis Bio's Chief Legal Officer To Leave Post This Week - Law360
One new option listing and ten option delistings on October 21st - TipRanks
Technical Analysis of Telesis Bio, Inc. (OTC:TBIO) - TradingView
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - TradingView — Track All Markets
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis - Yahoo Finance
Is Telesis Bio Inc. on the Brink of a Major Breakthrough? - timothysykes.com
Telesis Bio Inc. (NASDAQ: TBIO)Share Price - intelligentinvestor.com.au
Codex DNA stock plunges to 52-week low of $1.65 - Investing.com India
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market - Stock Titan
Telesis Bio reshuffles board, appoints new chairs - Investing.com India
Telesis Bio completes sale of subsidiary EtonBio - Investing.com
Yuan Yang completed the acquisition of Eton Bioscience, Inc. from Telesis Bio, Inc. - marketscreener.com
Enzymatic DNA Synthesis Market Size | Industry Report 2033 - Grand View Research
Telesis Bio, Inc. Approves Board Changes - MarketScreener
DNA Synthesis Market Size, Share | Growth Report [2025-2032] - Fortune Business Insights
Telesis Bio appoints new CEO as founder steps down - Investing.com
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results - Stock Titan
Press Release Service: Enzymatic DNA Synthesis Market to Surge to US$2.11 Billion by 2028 Driven by Advances in Synthetic Biology and Genetic Engineering TechnologiesResearchAndMarkets.com - CRISPR Medicine News
Telesis Bio: Q3 Earnings Snapshot - qz.com
New research finds that despite the stereotypes, women actually negotiate their salaries more than men - Fortune
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023 - FinancialContent
Enzymatic DNA Synthesis Market 2022: Explore Top Factors that Will Boost the Global Market by 2028 - openPR.com
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit - Technology Networks
Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock - The Globe and Mail
Telesis Bio, Inc. announced that it expects to receive $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor - marketscreener.com
Telesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023 - Koreabizwire
Eyepoint Pharmaceuticals (NASDAQ:EYPT), GeoVax Labs (NASDAQ:GOVX), Telesis Bio (NASDAQ:TBIO), Organovo Holdings (NASDAQ:ONVO), TRACON Pharmaceuticals (NASDAQ:TCON), and Abivax: Six Biotech Companies, Six Strategies - The Wall Street Transcript
Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up - Stock Titan
Telesis Bio Releases BioXp® Select mRNA Synthesis Kit To Expand the Utility, Speed and Impact of Its Automated Synthetic Biology Workstation - Technology Networks
Telesis Bio: Q4 Earnings Snapshot - KION Central Coast
Synthetic Biology Startup Molecular Assemblies Ships First DNA From New San Diego Facility - Forbes
What is the current Price Target and Forecast for TELESIS BIO (TBIO) - Zacks Investment Research
Automating DNA Synthesis Boosts Drug Discovery: - Mary Ann Liebert, Inc.
Global Cloning And Mutagenesis Market Size Report, 2030 - Grand View Research
Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 - Stock Titan
Codex DNA to Present at the 2022 Jefferies Healthcare Conference - Stock Titan
Codex DNA (NASDAQ:DNAY) CEO Todd Nelson Details the Investment Opportunity for mRNA and DNA Replication - The Wall Street Transcript
Interview with the President and CEO: Codex DNA, Inc. (NASDAQ:DNAY) - The Wall Street Transcript
Codex DNA, Pfizer Enter Collaboration to Develop mRNA-Based Vaccines and Biotherapies - MarketScreener
Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNAKeep An Eye On This Space - Seeking Alpha
Codex DNA Finishes 2021 Strong with Promising Pfizer Partnership - BioSpace
Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021 - Seeking Alpha
Louis Pasteur's Vaccine Successor Bets on mRNA - Bloomberg
Codex DNA Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - Stock Titan
DNAY IPO NewsSynthetic biology solutions provider Codex DNA prices IPO at $16 high end - renaissancecapital.com
Translate Bio (TBIO) Stock Live Price, Chart & News - CoinCodex
TBIOTRANSLATE BIO, INC. Latest Stock News & Market Updates - Stock Titan
Seth Klarman Says Fed Is Infantilizing Investors in ‘Surreal’ Market - Bloomberg.com
Novalis LifeSciences - Crunchbase
TBIO Stock Price | Telesis Bio Inc. Stock Quote (U.S.: OTC) - MarketWatch
Check out Telesis Bio's stock price (TBIO) in real time - CNBC
TBIO Stock Price and Chart — OTC:TBIO - TradingView
Telesis Bio, Inc. (TBIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
1.14%
0.05%
자본화:
|
볼륨(24시간):